This is a repository copy of Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/109312/

Version: Supplemental Material

Article:
Bell, R, Brown, JM orcid.org/0000-0002-2719-7064, Parmar, M et al. (18 more authors) (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Annals of Oncology, 28 (4). pp. 754-760. ISSN 0923-7534

https://doi.org/10.1093/annonc/mdw665

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. This is a pre-copyedited, author-produced PDF of an article accepted for publication in Annals of Oncology following peer review. The version of record, 'Bell, R, Brown, JM, Parmar, M et al (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Annals of Oncology, 28 (4). pp. 754-760,' doi: 10.1093/annonc/mdw665; is available online at: https://doi.org/10.1093/annonc/mdw665.

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Estimated probability

Time (months)

Events, N (%) 149 (11.6) 144 (11.1)
3-year OS rate, % 91.5 92.4
(95% CI) (89.9–93.1) (90.9–93.9)
5-year OS rate, % 87.7 87.9
(95% CI) (85.7–89.6) (86.0–89.8)
Stratified HR 0.93
(95% CI) (0.74–1.17)
Log-rank P value 0.5247

No. at risk

CT + BEV 1301 1264 1238 1205 1165 1122 1084 1053 1004 876 495 141 42 0
CT 1290 1248 1217 1175 1133 1089 1053 1019 976 862 511 122 41 0